Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Histone demethylases set the stage for cancer metastasis.

Cao J, Yan Q.

Sci Signal. 2013 Apr 30;6(273):pe15, 1-2. doi: 10.1126/scisignal.2004188. Review.

PMID:
23633674
2.

The role of histone demethylases in cancer therapy.

Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M.

Mol Oncol. 2012 Dec;6(6):683-703. doi: 10.1016/j.molonc.2012.07.004. Epub 2012 Aug 7. Review.

3.

The emerging role of histone lysine demethylases in prostate cancer.

Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD.

Mol Cancer. 2012 Aug 6;11:52. doi: 10.1186/1476-4598-11-52. Review.

4.

Epigenetic cancer therapy: Proof of concept and remaining challenges.

Mund C, Lyko F.

Bioessays. 2010 Nov;32(11):949-57. doi: 10.1002/bies.201000061. Review.

PMID:
21154865
5.

Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.

Morera L, Lübbert M, Jung M.

Clin Epigenetics. 2016 May 24;8:57. doi: 10.1186/s13148-016-0223-4. eCollection 2016. Review.

6.

Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, Booth CJ, Nguyen DX, Yan Q.

Cell Rep. 2014 Mar 13;6(5):868-77. doi: 10.1016/j.celrep.2014.02.004. Epub 2014 Feb 27.

7.

Histone lysine demethylases as targets for anticancer therapy.

Højfeldt JW, Agger K, Helin K.

Nat Rev Drug Discov. 2013 Dec;12(12):917-30. doi: 10.1038/nrd4154. Epub 2013 Nov 15. Review.

PMID:
24232376
8.

Roles of histone methyl-modifying enzymes in development and progression of cancer.

Suzuki T, Terashima M, Tange S, Ishimura A.

Cancer Sci. 2013 Jul;104(7):795-800. doi: 10.1111/cas.12169. Epub 2013 May 9. Review.

9.

Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.

Liu K, Liu Y, Lau JL, Min J.

Pharmacol Ther. 2015 Jul;151:121-40. doi: 10.1016/j.pharmthera.2015.04.001. Epub 2015 Apr 7. Review.

PMID:
25857453
10.

The future therapeutic potential of histone demethylases: A critical analysis.

Natoli G, Testa G, De Santa F.

Curr Opin Drug Discov Devel. 2009 Sep;12(5):607-15. Review.

PMID:
19736620
11.

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.

Gelato KA, Shaikhibrahim Z, Ocker M, Haendler B.

Expert Opin Ther Targets. 2016 Jul;20(7):783-99. doi: 10.1517/14728222.2016.1134490. Epub 2016 Jan 22. Review.

PMID:
26799480
12.

Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.

Bayo J, Dalvi MP, Martinez ED.

Future Med Chem. 2015;7(16):2243-61. doi: 10.4155/fmc.15.140. Epub 2015 Oct 29. Review.

PMID:
26510529
13.

The discovery of histone demethylases.

Shi YG, Tsukada Y.

Cold Spring Harb Perspect Biol. 2013 Sep 1;5(9). pii: a017947. doi: 10.1101/cshperspect.a017947. Review.

14.

Epigenetic regulation of cancer growth by histone demethylases.

Lim S, Metzger E, Schüle R, Kirfel J, Buettner R.

Int J Cancer. 2010 Nov 1;127(9):1991-8. doi: 10.1002/ijc.25538. Review.

15.

Targeting histone demethylases in cancer therapy.

Grant S.

Clin Cancer Res. 2009 Dec 1;15(23):7111-3. doi: 10.1158/1078-0432.CCR-09-2399. Epub 2009 Nov 24.

16.

The emerging roles for histone demethylases in the modulation of signaling pathways.

Di Stefano L, Dyson NJ.

Biomol Concepts. 2013 Feb;4(1):13-27. doi: 10.1515/bmc-2012-0031. Review.

PMID:
25436562
17.

Co-regulation of histone-modifying enzymes in cancer.

Islam AB, Richter WF, Jacobs LA, Lopez-Bigas N, Benevolenskaya EV.

PLoS One. 2011;6(8):e24023. doi: 10.1371/journal.pone.0024023. Epub 2011 Aug 23.

18.

Oncoepigenomics: making histone lysine methylation count.

Decarlo D, Hadden MK.

Eur J Med Chem. 2012 Oct;56:179-94. doi: 10.1016/j.ejmech.2012.08.010. Epub 2012 Aug 11. Review.

PMID:
22975593
19.

The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.

Pajtler KW, Weingarten C, Thor T, Künkele A, Heukamp LC, Büttner R, Suzuki T, Miyata N, Grotzer M, Rieb A, Sprüssel A, Eggert A, Schramm A, Schulte JH.

Acta Neuropathol Commun. 2013 May 29;1:19. doi: 10.1186/2051-5960-1-19.

20.

Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.

Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D, Han X, Yao Z, Shang Y.

Cancer Res. 2011 Nov 1;71(21):6899-908. doi: 10.1158/0008-5472.CAN-11-1523. Epub 2011 Sep 21.

Supplemental Content

Support Center